Dr Lars Grundemar | Assoc. Vice President, Experimental Medicine and Bioanalysis
Ferring Pharmaceuticals As

Lars Grundemar, M.D., Ph.D. is the Head of Experimental Medicine at Ferring Pharmaceuticals, Assoc. Vice President and based in Copenhagen, Denmark. He is responsible for early clinical development of compounds, mostly therapeutic peptides, but also biologics and small molecules.                                                 
Lars has established Experimental Medicine and Clinical Pharmacology departments and supported the build-up of translational medicine in R&D interfaces, as well as introduction of Personalized Medicine strategies in the US, Italy and Sweden at  Pharmacia/Pfizer. He has been engaged in Discovery Research and Clinical Development across multiple therapeutic areas.  Moreover, he has been leading Neuroscience in Early Clinical Development at Novartis and Astrazeneca, respectively. 
Lars is also an adjunct Professor the University of Lund, Sweden and before industry, he was a Physician and scientist combining experimental and clinical research and practice in Neuroscience.